Company / Return on Equity (ROE)
CHINA PHARMA HOLDINGS, INC. Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-14.0%
FY2025
5-year range
-92.6% / -14.0%
FY2021-FY2025
Trend
+66.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
CHINA PHARMA HOLDINGS, INC. reports negative total equity of -14.0% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-14.0% in FY2025 with a 5-year CAGR of +210.1%.
Improved from -41.3% to -14.0% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +78.6pp
- 5-Year Change
- +210.1pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 66.1% year-over-year.
- Lowest return on equity (roe) in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -0.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -14.0% | +66.1% |
| FY2024 | -41.3% | +0.0% |
| FY2023 | -41.3% | +55.4% |
| FY2022 | -92.6% | -158.6% |
| FY2021 | -35.8% | +84.0% |
| FY2020 | -224.1% | -529.5% |
| FY2019 | -35.6% | +20.5% |
| FY2018 | -44.8% | -187.1% |
| FY2017 | -15.6% | +26.5% |
| FY2016 | -21.2% | +61.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026